[go: up one dir, main page]

UY30557A1 - Tratamiento y prevencion de la fibrosis intestinal - Google Patents

Tratamiento y prevencion de la fibrosis intestinal

Info

Publication number
UY30557A1
UY30557A1 UY30557A UY30557A UY30557A1 UY 30557 A1 UY30557 A1 UY 30557A1 UY 30557 A UY30557 A UY 30557A UY 30557 A UY30557 A UY 30557A UY 30557 A1 UY30557 A1 UY 30557A1
Authority
UY
Uruguay
Prior art keywords
treatment
prevention
intestinal fibrosis
patient
formula
Prior art date
Application number
UY30557A
Other languages
English (en)
Inventor
John Parkinson
Stefano Fiorucci
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY30557A1 publication Critical patent/UY30557A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un método para tratar y prevenir la fibrosis intestinal en un paciente que necesita dicho tratamiento, que comprende administrarle al paciente una cantidad efectiva para el uso terapéutico de un compuesto análogo de lipoxina A4 de formula (I) o formula (II).
UY30557A 2006-08-23 2007-08-22 Tratamiento y prevencion de la fibrosis intestinal UY30557A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83975506P 2006-08-23 2006-08-23

Publications (1)

Publication Number Publication Date
UY30557A1 true UY30557A1 (es) 2008-03-31

Family

ID=39107156

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30557A UY30557A1 (es) 2006-08-23 2007-08-22 Tratamiento y prevencion de la fibrosis intestinal

Country Status (18)

Country Link
US (1) US20080119439A1 (es)
EP (1) EP2056816A2 (es)
JP (1) JP2010501506A (es)
KR (1) KR20090042982A (es)
CN (1) CN101528219A (es)
AR (1) AR062478A1 (es)
AU (1) AU2007287770A1 (es)
BR (1) BRPI0716576A2 (es)
CA (1) CA2660741A1 (es)
CL (1) CL2007002442A1 (es)
IL (1) IL196983A0 (es)
MX (1) MX2009001994A (es)
PE (1) PE20081360A1 (es)
RU (1) RU2009110244A (es)
TW (1) TW200816991A (es)
UY (1) UY30557A1 (es)
WO (1) WO2008022807A2 (es)
ZA (1) ZA200902005B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102036714A (zh) * 2008-05-22 2011-04-27 拜耳先灵医药股份有限公司 晶体2-((2s，3r，4e，6e，10e，12s)-13-(4-氟苯氧基)-2，3，12-三羟基十三碳-4，6，10-三烯-8-炔)氧基)乙酸的无水形式和水合物形式
US20140323550A1 (en) 2011-11-18 2014-10-30 Nitto Denko Corporation Intestinal fibrosis treatment agent
JP6906047B2 (ja) * 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
US20210401798A1 (en) * 2018-10-23 2021-12-30 The Brigham And Women's Hospital, Inc. Lipoxin a4 analogs and uses thereof
KR20250043287A (ko) 2023-09-21 2025-03-28 오토텔릭바이오 주식회사 티아졸 유도체 화합물을 포함하는 장섬유화증 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) * 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
US5441951A (en) * 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6006466A (en) * 1998-08-20 1999-12-28 Washecka; John Concealed linear payout holder for fishing leader
US6831186B2 (en) * 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs

Also Published As

Publication number Publication date
BRPI0716576A2 (pt) 2014-02-18
KR20090042982A (ko) 2009-05-04
US20080119439A1 (en) 2008-05-22
ZA200902005B (en) 2010-05-26
WO2008022807A3 (en) 2008-05-29
TW200816991A (en) 2008-04-16
AR062478A1 (es) 2008-11-12
WO2008022807A2 (en) 2008-02-28
AU2007287770A1 (en) 2008-02-28
CA2660741A1 (en) 2008-02-28
JP2010501506A (ja) 2010-01-21
CN101528219A (zh) 2009-09-09
IL196983A0 (en) 2009-11-18
PE20081360A1 (es) 2008-11-29
CL2007002442A1 (es) 2008-03-14
RU2009110244A (ru) 2010-09-27
EP2056816A2 (en) 2009-05-13
MX2009001994A (es) 2009-03-06

Similar Documents

Publication Publication Date Title
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
IL195030A (en) Dpp iv inhibitor formulations
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
AR074313A1 (es) Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo. uso. kit
AR083395A1 (es) Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
IL193252A0 (en) N-hydroxyacrylamide compounds
CL2012000586A1 (es) Uso de al menos 20 mg de un aerosol de una solucion que comprende levofloxacina u ofloxacina y un cation bivalente o trivalente, para el tratamiento de una infeccion pulmonar en un paciente con fibrosis quistica.
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.
BRPI0508333A (pt) uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit
AR043327A1 (es) Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170904